tbuckley/cabot-search huggingface dataset:
Does expression of estrogen receptor, progesterone receptor, and HER2 in atypical breast lesions predict a subsequent clinically significant event?
Authors: Judy Angela Tjoe, Gary Neitzel, Maharaj Singh, Brittany Last, James Marx, Sanjay Kansra
Journal: Journal of Clinical Oncology (2014)

34 Background: Atypical ductal hyperplasia (ADH) and atypical lobular hyperplasia (ALH) increase breast cancer risk 3-5 fold. Risk reduction strategies include intense radiographic surveillance, medical, or surgical prophylaxis, all with associated side effects. Thus, identifying predictors of future breast cancer associated with atypia would limit aggressive treatment to only those patients at highest risk for disease progression. Given that lifetime estrogen exposure is a risk factor for breast cancer, and human epidermal growth factor receptor-2 (HER2) gene amplification is linked to breast pathogenesis, we tested whether expression patterns of estrogen receptor (ER), progesterone receptor (PR), and HER2 at initial diagnosis of atypia predicted a subsequent clinically significant event (SCSE), defined as another occurrence of atypia, in situ, or invasive carcinoma. Methods: Patients with an initial diagnosis of ADH and/or ALH were retrospectively identified. 19 women who developed a SCSE (cases) were matched to 45 women with no SCSE for at least 5 years after the diagnosis of atypia (controls). Archived tissue from cases and controls were subjected to ER, PR, and HER2 immunohistochemistry. ER and PR were reported using Allred score (0 to 8). HER2 was reported as negative (0-1+), equivocal (2+) or positive (3+). Atypia with HER2 (2+) or (3+) scores were subject to SISH to confirm gene amplification. Results: There was no significant difference in expression of ER (mean Allred: cases = 7.26 ± 0.35; controls = 6.91 ± 0.43) or PR (mean Allred: cases = 6.95 ± 0.43; controls = 6.57 ± 0.34). &gt;90% of both cases and controls were HER2 negative (0-1+). Longitudinal assessment of ER, PR, and HER2 in patients who developed a SCSE revealed that three of 19 cases presented with HER2 overexpression; however SISH analysis revealed no gene amplification. Interestingly, ER/PR expression decreased in three of seven patients with atypia who later developed an invasive malignancy. Conclusions: ER and PR expression do not predict a SCSE after an initial diagnosis of breast atypia. HER2 does not appear to be a useful marker for risk prediction of a SCSE, as HER2 overexpression was not identified in any of our cases.
Serum B12 Levels In Children with Sickle Cell Disease Are Lower Than In Healthy Control Subjects
Authors: Oswaldo Castro, Mehdi Nouraie, Xiaomei Niu, Sohail Rana, Lori Luchtman-Jones, Andrew Campbell, Caterina Minniti, Gregory J. Kato, Mark Gladwin, Victor R. Gordeuk
Journal: Blood (2010)
Polyclonal Hypergammaglobulinemia in a Randomized Sample of Ghanaian Adult Males.
Authors: Francis Buadi, Jerry A. Katzmann, Ruth M. Pfeiffer, Ann W. Hsing, Edward D. Yeboah, Richard B. Biritwum, Angela Dispenzieri, Robert Kyle, Vincent Rajkumar, Ola Landgren
Journal: Blood (2007)
A Novel Mechanism of Action of Methyl-2-cyano-3,12 dioxoolean-1,9 diene-28-oate (CDDO-Me): Direct Permeabilization of the Inner Mitochondrial Membrane To Inhibit Electron Transport and Induce Apoptosis.
Authors: Ismael Samudio, Marina Konopleva, Helene Pelicano, Peng Huang, Olga Frolova, William Bornmann, Yun-ming Ying, Randall Evans, Michael Andreeff
Journal: Blood (2005)
Bendamustine Treatment in Refractory or Relapsed T Cell Lymphomas: A Retrospective Multicenter Study
Authors: Emilie Reboursiere, Fabien Le Bras, Franck Morschhauser, Emmanuel Gyan, Aline Clavert, Sandra Malak, David Sibon, Marion Damge, Claude Gardin, Luc-Matthieu Fornecker, Reda Garidi, Sabine Tricot, Roch Houot, Bertrand Joly, Wajed Abarah, Bachra Choufi, Anne-dominique Pham, Sylvain P Chantepie, Christophe Fruchart, Anne-Claire Gac, Catherine Ollivier, Emilie Marin, Violaine Safar, Anne Parcelier, Herve Maisonneuve, Emmanuel Bachy, Guillaume Cartron, Arnaud Jaccard, Olivier Tournilhac, Cedric Rossi, Aurore Perrot, Jean-Alain Martignoles, Herve Tilly, Gandhi Damaj
Journal: Blood (2015)
Overcoming the proliferation rate paradox: Clinical evaluation of a continuous dosing scheme of the novel oral Eg5 inhibitor 4SC-205.
Authors: Klaus B. Mross, Dirk Scharr, Heike Richly, Sebastian Bauer, Babett Krauss, Rolf Krauss, Bernhard Hauns, Tanja Prenzel, Hella Kohlhof, Roland Baumgartner, Max E. Scheulen
Journal: Journal of Clinical Oncology (2015)

2528 Background: Mitotic proteins, like Eg5, are exclusively expressed during mitosis. Targeted therapy directed against such proteins prevents side-effects like peripheral neuropathies. However, mitosis is a timely restricted event and doubling times of human solid tumours (~120d) largely exceed the ones observed in preclinical models. Therefore, continuous exposure at the target site is mandatory. Here we present a clinical dosing scheme for the Eg5i 4SC-205 to address these challenges Methods: Time-dependent anti-proliferative effect of 4SC-205 on spindle check point (SAC) deficient (H929, HT29) and proficient (HCT116, NCCIT) cell lines was investigated. Apoptosis induction was assessed by western blot analysis for Noxa, Mcl-1 and caspase 3. 59 patients (pts) with solid tumours were enrolled in a Phase I study and dosed either once weekly (ow) at days 1 and 8 or twice weekly (tw) at days 1, 4, 8, and 11 or continuously (con) within a 21-day cycle. Results: Effects on proliferation and apoptosis inductionin SAC deficient/proficient cell lines was time-dependent. SCA deficient cells required up to 96h incubation to establish the full IC50. 46 pts were enrolled in the discontinuous dosing arms with either once weekly (ow) or twice weekly (tw) (dose levels: 25mg (N = 3), 50mg (N = 3), 100mg (N = 6), 150mg (N = 6) and 200mg (N = 13) ow; at 50mg (N = 3), 75mg (N = 7), and 100mg (N = 5) tw). 13 patients were evaluated for con. dosing at 10mg (N = 3), 20mg (N = 6), and 30mg (N = 4). Response acc. to RECIST was not observed. Overall, 22% of pts. were stabilized into follow-up after 6 weeks. One patient is still on treatment at 20mg daily. The median time on study of pts receiving continuous dosing of 20 mg was 162 days. In contrast, the overall median time on study was 42 days under ow or tw dosing. Conclusions: Prolonged exposure is needed for 4SC-205 to inhibit proliferation and to induce apoptosis in SAC deficient cell lines. This requirement was translated into the clinic utilizing a continuous dosing scheme. 4SC-205 can be safely administered at an oral daily dose of 20mg ( = RP2D). Promising long-term disease stabilization is observed under continuous dosing. Clinical trial information: NCT01065025.
Assessment of Clonal Evolution in 42 AML with NPM1 Mutations by Molecular Characterization of Paired Diagnosis and Relapse Samples
Authors: Jan Krönke, Lars Bullinger, Frank G. Rücker, Verena I. Gaidzik, Michael WM Kühn, Karin Bezet, Veronica Teleanu, Peter Paschka, Daniela Späth, Thomas Kindler, Helmut R. Salih, Jürgen Krauter, Arnold Ganser, Gudrun Göhring, Brigitte Schlegelberger, Richard F. Schlenk, Hartmut Döhner, Konstanze Döhner
Journal: Blood (2011)
Treatment of patients with metastatic colorectal cancer in a real-word scenario: probability of being submitted and clinical benefit of second and further lines of therapy
Authors: M.P. Brizzi, C. Baratelli, M. Di Maio, C. Sonetto, P. Bironzo, A. La Salvia, G.V. Scagliotti, M. Tampellini
Journal: Annals of Oncology (2016)
<i>JAK</i> Mutations as Escape Mechanisms to Anti–PD-1 Therapy
Authors: Aurelien Marabelle, Sandrine Aspeslagh, Sophie Postel-Vinay, Jean-Charles Soria
Journal: Cancer Discovery (2017)

Abstract Summary: JAK mutations could be one of the primary escape mechanisms to anti–PD-1/PD-L1 immunotherapy via impaired IFNγ signaling in cancer cells and could be used to identify patients unlikely to benefit from these treatments. Cancer Discov; 7(2); 128–30. ©2017 AACR. See related article by Shin et al., p. 188.
Changes in production of total immunoglobulin E but not food allergen-specific IgE or IgG4 in at-risk children after exposure to aluminum adjuvant.
Authors: Alice E.W. Hoyt, Alexander J. Schuyler, Lisa J. Workman, Mark Conaway, Peter W. Heymann, John W. Steinke, Larry Borish, Thomas A.E. Platts-Mills
Journal: Journal of Allergy and Clinical Immunology (2017)
487P Real-world feasibility of adjuvant TAC with pegylated G-CSF in resectable breast cancer: A single-center experience
Authors: J.H. Park, B. Kwon, J.-H. Ahn, J.E. Kim, K.H. Jung, G. Gong, H.J. Lee, B.-H. Son, S.-H. Ahn, H.-H. Kim, H.J. Shin, D. Moon, S.B. Kim
Journal: Annals of Oncology (2016)
Rituximab Maintenance after Autologous Stem Cell Transplantation Prolongs Survival in Younger Patients with Mantle Cell Lymphoma: Final Results of the Randomized Phase 3 LyMa Trial of the Lysa/Goelams Group
Authors: Steven Le Gouill, Catherine Thieblemont, Lucie Oberic, Anne Moreau, Krimo Bouabdallah, Emmanuel Gyan, Gandhi Damaj, Vincent Ribrag, Pierre Feugier, Olivier Casasnovas, Hacene Zerazhi, Corinne Haioun, Hervé Tilly, Olivier Tournilhac, Herve Maisonneuve, Philippe Solal-Celigny, Luc Mathieu Fornecker, Eric W Van Den Neste, Danielle Canioni, Gilles Salles, Thierry Lamy, Marie-Christine Bene, Remy Gressin, Olivier Hermine
Journal: Blood (2016)
3-biomarker HRD score versus individual biomarker (LOH, TAI, LST) scores in platinum treated serous ovarian cancer (SOC)
Authors: J. Lanchbury, K. Timms, J. Reid, E. Stronach, A. Gutin, T. Krivak, B. Hennessy, J. Paul, R. Brown, R. Nix, Z. Sangale, E. Hughes, V. Abkevich, G.B. Mills
Journal: Annals of Oncology (2016)
Seasonal Effect of Eicosanoids on Pulmonary Function in Asthma with Concomitant Rhinitis Caused By Japanese Cedar Pollinosis.
Authors: Yoshitaka Uchida, Tomoyuki Soma, Kazuyuki Nakagome, Yotaro Takaku, Rie Hoshi, Makoto Nagata
Journal: Journal of Allergy and Clinical Immunology (2017)
Geriatric Assessment Metrics Are Associated with Hospital Length of Stay in Pre-Bone Marrow Transplant Myeloma Patients
Authors: Ashley E Rosko, Craig C Hofmeister, Yvonne A Efebera, Don M Benson, Douglas W Sborov, Samantha Jaglowski, Steve Devine, Tanya M Wildes, James Gillahan, Desiree Jones, Ying Huang, Christin E Burd
Journal: Blood (2015)
Amifostine Reduces High-Dose Melphalan Induced Gastro-Intestinal Toxicity in Autologous Hematopoietic Cell Transplant (HCT) for Plasma Cell Myeloma
Authors: Vinita Gupta, Hulya Armutlugoynuk, Anant Vatsayan, Paolo F. Caimi, Brenda Cooper, Leland Metheny, Ehsan Malek, Erica L. Campagnaro, Stan Gerson, Marcos de Lima, Hillard M. Lazarus, Richard J Creger
Journal: Blood (2015)
Pomalidomide (CC4047) Plus Low Dose Dexamethasone (Pom/dex) Is Active and Well Tolerated in Lenalidomide Refractory Multiple Myeloma (MM).
Authors: Martha Q. Lacy, Morie A Gertz, Suzanne R. Hayman, Kristen Detweiler Short, Angela Dispenzieri, Shaji Kumar, Steven R. Zeldenrust, Philip R. Greipp, John A. Lust, Stephen J. Russell, Francis Buadi, Robert Kyle, Rafael Fonseca, P. Leif Bergsagel, Vivek Roy, Joseph R. Mikhael, A. Keith Stewart, Craig B. Reeder, David Dingli, Jacob Allred, Kristina Laumann, Sumithra Mandrekar, S. Vincent Rajkumar
Journal: Blood (2009)
Transcriptomic analysis of collecting duct carcinoma of the kidney
Authors: A. Tessari, I. Testa, E. Verzoni, G. Nigita, M. Colecchia, D. Palmieri, P. Grassi, M. Pawlikowski, C. Maggi, A. Martinetti, F. de Braud, C.M. Croce, G. Procopio
Journal: Annals of Oncology (2016)
Nasal Group 2 Innate Lymphoid Cells Accumulate during COX-1 Inhibition in Aspirin- Exacerbated Respiratory Disease
Authors: Jacqueline J. Eastman, Kellen J. Cavagnero, Adam S. Deconde, Alexander S. Kim, David H. Broide, Bruce L. Zuraw, Andrew A. White, Sandra C. Christiansen, Taylor Alan Doherty
Journal: Journal of Allergy and Clinical Immunology (2017)
Central Nervous System (CNS) Relapse In a Population of 143 Patients (Pts) with Mantle Cell Lymphoma (MCL) From Two Centers
Authors: Annarita Conconi, Silvia Franceschetti, Chiara Lobetti-Bodoni, Anastasios Stathis, Riccardo Bruna, Paola Riccomagno, Francesco Bertoni, Michele Ghielmini, Franco Cavalli, Gianluca Gaidano, Emanuele Zucca
Journal: Blood (2011)
The Pink Ribbon Survivors Network: An Internet resource for breast cancer survivorship education for patients and the health care providers that care for them.
Authors: Robert E. Fisher, Kelly Ann Adams
Journal: Journal of Clinical Oncology (2012)

329 Background: The authors identified a need to provide three online tools for the benefit of breast cancer survivors and health care providers: 1) An online collection of relevant publications from all cancer specialties regarding breast cancer survivorship housed in one virtual library. 2) An online collection of guidelines and relevant publications as a resource for primary care providers to access clinical information on medical care and psychosocial issues regarding breast cancer survivorship. 3) An online collection of resources, organizations, and supportive programs and selected readings for breast cancer survivors. These readings would be organized in a "Curriculum for Recovery" Library. We were motivated by the belief that, "all breast cancer survivors are underserved, if their healthcare providers are undereducated." Methods: Using the Joomla software system, a free, online website has been developed. This site houses the three virtual libraries, on separate landing pages, described above. Additional resources for breast cancer survivors are also housed on the website. Results: The Pink Ribbon Survivors Network now provides a resource of over 500 separate listings designed to educate and support breast cancer survivors, and health care professionals. The online professional libraries were created from abstracts available from medical journals and similar mainstream oncology publications. The libraries are continuously updated with new publications. These collective libraries will serve as unique breast cancer survivorship tools for women and their health care providers, for new publications, and for resources. Conclusions: This abstract establishes that a system using internet technology can provide virtual resources for breast cancer survivors, cancer specialists, and primary health care providers. This is now a functional online system for the 2.5 million breast cancer survivors and nearly 500,000 health care providers involved in the care of these survivors. The organization’s website is www.PinkRibbonSurvivorsNetwork.org.
The Mutation Spectrum of CML Patients Resistant to Imatinib: More Heterogeneous Than Just BCR-ABL Kinase Domain Point Mutations?.
Authors: Tuija Lundan, Franz Gruber, Aleksandra Silye, Henrik Hjorth-Hansen, Ingvild Mikkola, Kari Remes, Bengt Simonsson, Tobias Gedde-Dahl, Kimmo Porkka
Journal: Blood (2007)
Stool Edn Levels in Different Clusters of Non-IgE-Mediated Gastrointestinal Food Allergy
Authors: Kanami Orihara, Ichiro Nomura, Tetsuo Shoda, Hiroko Suzuki, Hideaki Morita, Akio Matsuda, Hirohisa Saito, Kenji Matsumoto
Journal: Journal of Allergy and Clinical Immunology (2017)
Health behaviors in survivors of aggressive NHL.
Authors: Allison Claire Rosenthal, Matthew J. Maurer, Cristine Allmer, Stephen Maxted Ansell, Umar Farooq, Thomas Matthew Habermann, Brian K. Link, Thomas E. Witzig, Kathleen J. Yost, James Robert Cerhan, Carrie A. Thompson
Journal: Journal of Clinical Oncology (2016)

236 Background: Patients (pts) with aggressive lymphoma are generally treated with curative intent and many become long-term survivors. There is little data on health behaviors after lymphoma diagnosis and their effect on QOL and long-term outcomes. Methods: Lymphoma pts were prospectively enrolled within 9 months of diagnosis in the University of Iowa/Mayo Clinic SPORE Molecular Epidemiology Resource (MER) and systematically followed. We measured QOL (FACT-G) and health behaviors (tobacco/alcohol use; diet/exercise habits) 3 years after diagnosis. For this study, “survivor” was defined as alive at 3 years from diagnosis with no active disease or treatment within the previous year. Results: From 2002-2012, 671 patients with aggressive lymphoma were enrolled, met survivor definition, and completed 3-year QOL and health behavior questionnaires. At 3-years, 31% of female (F) and 48% of male (M) reported a history of tobacco use for 6+ months. Of these, 13% of F and 7% of M were still smoking; 52% reported decreased use from baseline. 66% reported no change in alcohol intake at 3-years while 25% of F and 34% of M reported decreased intake. 60% often chose whole grains and 65% get 2+ servings of vegetables daily. 42% of F and 38% of M “somewhat” believed diet could change the course of their lymphoma. Most pts endorsed no significant change in diet as a result of diagnosis. Those who made changes did so primarily out of concern for “health problems other than cancer”. Overweight/obese responders were 72% pre- and 66% post-treatment. A desire to lose weight was reported by 55% of pts. 14% of F and 23% of M often engaged in regular physical activity (PA). Nearly 50% reported a decrease in PA. Pts with advanced stage (p = 0.006), age &gt; 60 (p = 0.001), ECOG PS &gt; 2 (p = 0.04), and worse prognostic score (p = 0.006) were more likely to report decreased PA since diagnosis. 68% of F and 61% of M intend to become more active in the next months. Regular PA (p = &lt; 0.0001) was associated with higher QOL, while increased alcohol intake was associated with lower QOL (p = 0.009) at 3 years. Conclusions: Many survivors of aggressive NHL strive to adopt healthy behaviors and these behaviors are associated with higher QOL. Interventions aimed at emphasizing these behaviors may have potential to improve long-term outcomes and QOL.
Efficacy and safety of dose-dense taxotere cisplatin fluorouracil regimen (mTCF-dd) in a large cohort of patients (pts) with metastatic or locally advanced non-squamous gastroesophageal cancer (GEC)
Authors: L. Toppo, G. Tomasello, M. Ghidini, C. Caminiti, G. Maglietta, S. Lazzarelli, W. Liguigli, M. Rovatti, V. Ranieri, G. Tanzi, F. Buffoli, M. Martinotti, R. Passalacqua
Journal: Annals of Oncology (2016)
Impact of surgical resection of liver metastases on outcome of patients with KRAS-wildtype exon 2 (KRAS-wt) metastatic colorectal carcinoma (mCRC) treated with a cetuximab-based first-line therapy - Interim analysis of the German non-interventional study ERBITAG
Authors: U. Neumann, T. Goehler, C. Hering-Schubert, J. Janssen, S. Sahm, M. Schwittay, M.O. Zahn, K.G. Stenzel, F. Overkamp
Journal: Annals of Oncology (2016)
Use of early radiation therapy in the palliative local treatment of stage IV esophageal cancer.
Authors: Lauren Michelle Hertan, John Peter Plastaras, Edgar Ben-Josef, James M. Metz, Joshua Adam Jones, Smith Apisarnthanarax
Journal: Journal of Clinical Oncology (2014)

198 Background: Palliating local symptoms in stage IV esophageal cancer remains a challenge with no clear optimal initial intervention. Therapeutic options include radiation therapy (RT), chemotherapy (chemo), stent, or a combination of these treatments. We hypothesized that early initial RT would result in the best palliation of local symptoms in stage IV esophageal cancer patients. Methods: The study cohort included 72 patients with locally symptomatic stage IV esophageal cancer treated at the University of Pennsylvania from 2006-2012 and was split into those who received RT as part of their initial treatment (n = 42) versus those who did not (n=30; chemo alone, n = 18; chemo and stent, n = 9; stent alone, n=3). Demographics, baseline disease characteristics, treatment details, and clinical outcomes were analyzed. Results: Patient demographics and baseline characteristics were well balanced between the groups, except the RT group was less likely to have liver metastases (p=0.001). The RT group included both concurrent chemoRT (n=31) and RT alone (n=11, with or without sequential chemo). Median RT dose was 50.4 Gy (range 21 – 70 Gy). Chemotherapy regimens included 5-FU based or Carboplatin/Paclitaxel. Presenting symptoms included dysphagia (n=69, median grade 2), odynophagia (n=3, median grade 1), bleeding (n=5, median grade 3), and chest pain (n=3, median grade 2). No difference was noted in symptom improvement (median grade improvement = 1; p=0.25) or ECOG status (median improvement = 0; p=0.24) between the groups. However, patients who received upfront RT were less likely to have local symptom progression (% not having symptom progression: 69.1% [RT] v 43.3% [no RT]; p=0.003) and less likely to need repeat local intervention (% not requiring repeat local intervention: 81.0% [RT] v 33.3% [no RT]; p&lt;0.0001). There was no difference in median time to first progression (11 mo [RT] v 11 mo [no RT]) or median survival (9.8 mo [RT] v 10.7 mo [no RT]). Conclusions: Early use of RT in locally symptomatic stage IV esophageal cancer patients results in effective palliation of local symptoms that may be more sustained compared to chemo alone or stent placement.
414TiP An open-label phase 2a study of combination dabrafenib (D) and trametinib (T) in Asian patients (pts) with advanced BRAF V600-mutant acral lentiginous melanoma (ALM) or cutaneous melanoma (CM)
Authors: J. Guo, W.-C. Chang, A. Dechaphunkul, Y. Fan, T.M. Kim, C.-C. Lin, J. Maneechavakajorn, S.J. Shin, X. Song, S.-T. Cheng, S. Thongprasert, B.S. Wong, D. Wu, X. Zhang, S. Bettinger, P. Zhang, B. Mookerjee
Journal: Annals of Oncology (2016)
Differential Expression of Neutrophil Granule Protein Genes in Bone Marrow Myeloid Cells at the Peak and Nadir of Neutrophil Counts in Cyclic Neutropenia
Authors: Olga Klimenkova, Maksim Klimiankou, Lothar Kanz, Cornelia Zeidler, Karl Welte, Julia Skokowa
Journal: Blood (2015)
Correlation between programmed death-ligand 1 (PD-L1) expression and T790M status in EGFR-mutant non-small cell lung cancer (NSCLC)
Authors: A. Hata, N. Katakami, S. Nanjo, C. Okuda, R. Kaji, K. Masago, S. Fujita, Y. Imai
Journal: Annals of Oncology (2016)
Ramucirumab as second line therapy in metastatic gastric cancer (MGC): results of the Italian compassionate-use named patients. The RAMoss study
Authors: F. De Vita, M. Niger, C. Vivaldi, E. Giommoni, A. Zaniboni, S. Bozzarelli, G. Tomasello, T. Sava, M. Spada, E. Menatti, I. Proserpio, S. Galdy, A. Bittoni, K. Bencardino, M. Squadroni, T.P. Latiano, A. Spallanzani, G. Tirino, A. Petrillo, M. Di Bartolomeo
Journal: Annals of Oncology (2016)
Telomere Length Measurement by Flow-FISH Distinguishes Dyskeratosis Congenita from Other Bone Marrow Failure Syndromes.
Authors: Blanche P. Alter, Gabriela Baerlocher, Sharon A. Savage, Stephen Jacob Chanock, Babette B. Weksler, Judith P. Willner, June A. Peters, Peter M. Lansdorp
Journal: Blood (2006)
Genome-wide association study unravels genetic determinants of the atopic march
Authors: I. Marenholz, J. Esparza-Gordillo, F. Rueschendorf, D. P. Strachan, B. D. Spycher, H. Baurecht, P. Margaritte-Jeannin, A. Saeaef, M. Kerkhof, M. Ege, S. Baltic, M. C. Matheson, J. Li, S. Michel, W. Q. Ang, W. McArdle, G. Homuth, E. Bouzigon, G. Pershagen, D. S. Postma, C. Braun-Fahrlaender, D. L. Duffy, G. B. Marks, C. F. Robertson, N. G. Martin, A. James, P. Sleiman, R. Foelster-Holst, W. Lieb, C. Gieger, E. Rietschel, T. Keil, M. M. Noethen, P. D. Sly, C. O. Schmidt, A. Matanovic, Pg P. G. Holt, S. Lau, M. Kabesch, S. Weidinger, H. Hakonarson, M. A. R. Ferreira, C. Laprise, M. B. Freidin, J. Genuneit, G. H. Koppelman, E. Melen, M.-H. Dizier, A. J. Henderson, Y.-A. Lee
Journal: Allergy (2016)
Prognostic Impact of Hematopoietic Recovery After Fludarabine, IV Busulfan and Antithymocyte Globulins (FB2 regimen) Reduced-Intensity Conditioning Regimen (RIC) Allogeneic Stem Cell Transplantation (allo-SCT)
Authors: Amandine Lebourgeois, Marion Loirat, Benoit Tessoulin, Elsa Lestang, Pierre Peterlin, Florent Malard, Catherine Mohr, Cyrille Touzeau, Nicolas Blin, Aline Clavert, Karine Augeul-Meunier, Thierry Guillaume, Jacques Delaunay, Sameh Ayari, Eolia Brissot, Viviane Dubruille, Beatrice Mahe, Virginie Roland, Thomas Gastinne, Steven Le Gouill, Philippe Moreau, Mohamad Mohty, Lucie Planche, Patrice Chevallier
Journal: Blood (2012)